Development | Vaccine | Against Tuberculosis
Against Tuberculosis
To date, the only registered and widely used vaccine is BCG, derived from an attenuated strain of Mycobacterium bovis and first administered to humans in 1921. We have developed several next-generation tuberculosis vaccine candidates.
Composition and Mechanism of Action
The foundation consists of recombinant proteins designed to induce a specific immune response against Mycobacterium tuberculosis, including fragments of Ag85B and Tb10.4 proteins, along with an adjuvant—flagellin fragments (FliC) from S. Typhimurium. A modified composition also incorporates plasmid DNA encoding Ag85A and/or Ag85B proteins of M. tuberculosis.
Efficacy and Safety
The proposed vaccines demonstrate higher efficacy than BCG. Their safety is ensured by the use of recombinant proteins and/or plasmid DNA, eliminating risks associated with introducing even inactivated or attenuated bacteria into the body.
Against Tuberculosis
To date, the only registered and widely used vaccine is BCG, derived from an attenuated strain of Mycobacterium bovis and first administered to humans in 1921. We have developed several next-generation tuberculosis vaccine candidates.
Composition and Mechanism of Action
The foundation consists of recombinant proteins designed to induce a specific immune response against Mycobacterium tuberculosis, including fragments of Ag85B and Tb10.4 proteins, along with an adjuvant—flagellin fragments (FliC) from S. Typhimurium. A modified composition also incorporates plasmid DNA encoding Ag85A and/or Ag85B proteins of M. tuberculosis.
Efficacy and Safety
The proposed vaccines demonstrate higher efficacy than BCG. Their safety is ensured by the use of recombinant proteins and/or plasmid DNA, eliminating risks associated with introducing even inactivated or attenuated bacteria into the body.
Patent Applications
Eurasian Patent Application No. 201791906 (filed 24.09.2017)
Eurasian Patent Application No. 201600347 (filed 24.05.2016)
Russian Patent Application No. 2008149821 (filed 18.12.2008)
Awards
2019 Silicon Valley, USA
2017 New Time Salon, Sevastopol – Diploma, Silver Medal
2017 — Salon "New Time", Sevastopol. Diploma. Gold medal
2017 Archimedes Salon, Moscow – Diploma, Silver Medal
2018 International Fair of Technics and Technical Achievements, Belgrade
Patents
Application No. 031495: Tuberculosis vaccine based on recombinant proteins Ag85B, TB10.4, FliC
Would you like us to develop a custom drug?
Leave your request, and we will contact you.
Сообщение об успешной отправке!
Phone:
Email:
